Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital

Jörg M. Steiner, Panagiotis G. Xenoulis, Joseph A. Anderson, A. Catherine Barr, David A. Williams

Research output: Contribution to journalArticlepeer-review

Abstract

Potassium bromide, phenobarbital, or a combination of both is commonly used in the treatment of canine epilepsy. Several cases of clinical pancreatitis have been reported in dogs after treatment with potassium bromide, but the risk of elevated serum canine pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital has not previously been evaluated in a large group of dogs. This study suggests an increased risk for elevated serum canine pancreatic lipase immunoreactivity concentrations and possibly pancreatitis in dogs treated with potassium bromide or phenobarbital alone or in combination.

Original languageEnglish (US)
Pages (from-to)37-44
Number of pages8
JournalVeterinary Therapeutics
Volume9
Issue number1
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint

Dive into the research topics of 'Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbital'. Together they form a unique fingerprint.

Cite this